CAI vs TECH · rev $216.8M vs P/E 65, rev $1.22B
Caris Life Sciences, Inc. Common Stock (CAI) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
CAI currently screens at market cap $5.22B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the CAI and TECH stock pages for the full models.
Not investment advice.